significant new advance to prevent serious respiratory syncytial virus (RSV) infections in young children

November 1998

There's a significant new advance to prevent serious respiratory syncytial virus (RSV) infections in young children.

It's called Synagis (palivizumab)...for preemies and young children with lung disease who are at risk for pulmonary RSV infections.

Synagis is a monoclonal antibody. It binds to a protein on the surface of the virus to prevent it from infecting cells.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote